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Introduction Neuropsychiatric symptoms are widely reported in asso-
ciation with both hepatitis C and IFNα treatment [1]its se-quelae, and its treatment. In particular, interferon, a primary component of treatment for chronic hepatitis C, has been strongly associated with depressive symptoms. This review summarizes current knowledge about the etiology, course, and treatment of neuropsychiatric problems associated with hepatitis C and interferon alpha (IFN-alpha and lead to dis-
continuation of interferon in up to 13% of cases [2]. During both acute and chronic stages of hepatitis C, cog-nitive, affective and behavioral symptoms are frequently 
reported (60-20%). When on interferon treatment, these symptoms are not easily distinguished from each other or 
from depression [2,3]mechanism, course, and treatment of neuropsychiatric problems associated with interferon alfa (IFN-alpha. Beside these, almost all patients who are treated 
with IFN-α experience an acute flu-like syndrome hours af-
ter the initial injection. Only after a few weeks of treatment, fatigue, malaise, apathy, cognitive and behavioral changes commonly develop. 
Neurological side effects appear in 1/3 of patients during 
IFN-α therapy [3]mechanism, course, and treatment of neuropsychiatric problems associated with interferon alfa (IFN-alpha. Peripheral neuropathy including demyelinating 
polyneuropathy related to IFN is extremely rare [2]. IFN-α 2a showed to have caused peripheral sensory neuropathy given 
for a period of twenty months [2] and we know that some patients develop antibodies to peripheral nerves antigens during treatment, but its pathogenicity has not been proved.Neuropsychiatric symptoms like mania and hypomania are considered a rare occurrence. Yet, an European study found 
that 20% of patients receiving pegylated IFNα plus ribavi-rin for HCV developed maniac and hypomaniac symptoms 
at some point during the 24 weeks of treatment [4]. To ease diagnostic skills some authors pointed out some possible 
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risk factors for psychiatric side effects of IFN-α: dose and ap-
plication form (intravenous > intramuscular > subcutaneous), older age, organic brain injury or dysfunction, drug and alco-hol abuse, HIV infection, depression, a premorbid personality 
or a personality disorder [3].The majority of these disturbances disappear with cessation of 
IFN-α. However in some patients serious affective or psychotic symptoms persist for many months despite adequate therapy 
[3]. Clinicians should be aware of the challenge of diagnosing 
[5]. 
To our knowledge this is the first somatoform disorder de-scribed while on peginterferon based therapy for hepatitis C.
Case Report
A 47-year old woman followed at our clinic with a history of drug addiction, depression, and co-infection HCV (genotype 
3a) / HIV1 stage B2 with virological suppression for many 
years, under tenofovir+emtricitabine and lopinavir/r. She had 
a moderate fibrosis (METAVIR score F2) and began treatment 
with peginterferon alpha2b (1.5 µg/kg/wk) and ribavirin 
(800mg/daily). 
In the first weeks of treatment she complained of sleep distur-
bances, anxiety and flu-like syndrome. Starting from this point 
she assumed alprazolam 1mg bid and fluoxetine 20mg id with apparent symptomatic control. 
Rapid clinical and virological responses were achieved. At 
week 15 she emerges with tingling, numbness and weakness, complaining of a right lumbar paresthesia and paresis of the ipsilateral lower limb, with inbalance and falls. On the initial 
neurological examination she had a right crural hemiplegia 
(proximal and distal segment), flabby tonus but with brisk and 
symmetrical osteotendinous reflexes, cutaneoplantar reflex bi-
laterally in flexion, plain anesthesia to touch, pinprick test and temperature sensation, and no proprioceptive sensitivity. Sur-prisingly, she had a positive Hoover maneuver making more likely the suspicion of somatization. However, she couldn’t walk by herself, using a wheelchair. Brain CT, lumbar and dor-
sal MRI, cerebrospinal fluid and electromyography were nor-mal. She still complained about her lack of locomotion and, within one week, she developed inappropriate behavior, with verbiage and persecutory ideas. Her laboratory tests included a normal blood count, chemistry 
profile and C-reactive protein. Antinuclear and antiganglioside antibodies, rheumatoid factor, serum crioglobulin level, Ep-stein-barr and cytomegalovirus serology were tested negative. Imunoelectrophoresis for monoclonal antibodies in cerebro-
spinal fluid, thyroid function and B12 vitamin were normal. 
Organic causes were excluded and the psychiatric evaluation and workout, concluded for a somatoform disorder and psy-
chosis. Peginterferon alpha2b and ribavirin were suspended at 
week20. She was submitted to physiotherapy and optimization of psychiatric therapy (aripiprazole 15 mg/day) that she kept for one year round and gradually recovering humor (currently 
controlled) and sensitive and motor pseudo deficits (now re-
covered). By now she has a sustained virological response. 
Discussion
In 2015  we have access to multiple highly effective, tolerable 
and safe antivirals for the treatment of hepatitis C virus (HCV) 
infection. We are able to forego the use of interferon-α (IFNα) and, for many patients, ribavirin is no longer needed. Neuro-psychiatric symptoms management implies dose reduction and discontinuation of interferon that can be effective for ma-nia, depression and other interferon-related neuropsychiatric syndromes, but when the psychopathology is severe or per-sistent, pharmacotherapy with psychotropic agent is neces-
sary [3]mechanism, course, and treatment of neuropsychiatric 
problems associated with interferon alfa (IFN-alpha. Mania, especially when severe, is a clinical emergency. Under close monitoring and adequate treatment mania doesn’t necessarily require discontinuation of IFN therapy. If mania is severe or 
difficult to control, IFN should be discontinued, but resuming antiviral treatment should be considered after remission of 
mania symptoms [3]mechanism, course, and treatment of neu-ropsychiatric problems associated with interferon alfa (IFN-al-
pha.  Generally, neuropsychiatric symptoms seem to improve 3 
to 4 days after the dose of conventional IFN therapy is reduced, 
although compromising optimal dosing and efficacy. There-fore, current evidence supports managing the patient without changing the IFN dose in order to optimize treatment outcome 
[5]which can significantly compromise epidemiological virus control. This review summarizes current knowledge about the etiology, course, and management of neuropsychiatric symp-
toms in patients with CHC.\n\nMETHOD: Studies were iden-
tified using computerized searches, with further references obtained from the bibliographies of the reviewed articles.\n\
nRESULTS: Psychopathological syndromes that occur during interferon-alpha treatment frequently have atypical features that may complicate their recognition using standard diagnos-tic criteria. In addition, prospective studies in this area often 
exclude patients with psychiatric disorders and have method-
ological disparities that make it difficult to develop guidelines for management of psychiatric side effects induced by interfer-on-alpha. Despite the high prevalence of chronic hepatitis C vi-rus (HCV. Our patient had typical complains related to IFN side effects during treatment. The last five weeks were ultimately decisive to the suspension of the therapy, not only because we were thinking about a peripheral neuropathy, that surprisingly was somatization not widely described, but also for the pro-cess of mania that was a psychiatric emergency. However, she 
completed 20 wk of therapy without relapse of the disease and 
recovered the deficits. 
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Coinfected persons appear to have a greater number of somat-ic concerns than do persons with HIV or HCV infection alone. However, coinfected persons do not report more neuropsychi-atric symptoms or higher prevalence of other psychiatric dis-orders than do monoinfected persons.Nowadays, there is a growing consensus about the importance 
of diagnosing and treating depressive and anxious symptoms in all patients being considered for IFN treatment, even when the symptoms are subclinical, as well as the need to regular-
ly assess for such symptoms during treatment [5]which can 
significantly compromise epidemiological virus control. This review summarizes current knowledge about the etiology, course, and management of neuropsychiatric symptoms in pa-
tients with CHC.\n\nMETHOD: Studies were identified using computerized searches, with further references obtained from 
the bibliographies of the reviewed articles.\n\nRESULTS: Psy-chopathological syndromes that occur during interferon-alpha treatment frequently have atypical features that may compli-cate their recognition using standard diagnostic criteria. In ad-
dition, prospective studies in this area often exclude patients with psychiatric disorders and have methodological disparities 
that make it difficult to develop guidelines for management of psychiatric side effects induced by interferon-alpha. Despite the high prevalence of chronic hepatitis C virus (HCV. Patients 
should be screened regularly for depression during the first 
six months of IFN therapy. Monitoring every 2-4 weeks during 
the first 3 months of hepatitis treatment appears sufficient for identifying patients who may require psychiatric interven-
tion [3]mechanism, course, and treatment of neuropsychiatric problems associated with interferon alfa (IFN-alpha.
Learning points
•	 Neuropsychiatric symptoms are widely reported in 
association with both hepatitis C and interferon-α 
(IFNα) treatment and lead to discontinuation of inter-feron.
•	 Patients proposed for IFN therapy should be screened 
regularly for depression during the first six months of 
IFN therapy. Monitoring every 2-4 weeks during the 
first 3 months may be sufficient for identifying pa-tients who may require psychiatric intervention.
•	 Somatoform disorders are not easy to diagnose un-der IFN therapy. Although, the majority of neuropsy-chiatric disturbances disappear with cessation of 
IFN-α, however in some subjects serious affective or psychotic symptoms may continue for many months despite adequate therapy.
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